Pyxis Oncology, Inc.
Pyxis Oncology, Inc. (PYXS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pyxs · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$5.50
+225.4% upside
Low
$5.00
Median: $5.5 · Last Close: $1.69
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$5.50
225.4% upside
High Target
$6
255.0%
Low Target
$5
195.9%
Current Price
$1.69
as of today
Based on analyst price targets, the PYXS stock price prediction for the next 12 months ranges from $5 to $6. The consensus PYXS price forecast of $5.50 implies 225.4% upside from the current price of $1.69.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.61 | ↓ 5.00% |
1-day model range: $1.58–$1.63. Peak: $1.63 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PYXS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-24 | Stifel | Maintains | Buy→Buy |
| 2026-03-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-19 | RBC Capital | Maintains | Outperform→Outperform |
| 2025-12-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-24 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2025-11-04 | Guggenheim | Maintains | Buy→Buy |
| 2025-08-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-19 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Pyxis Oncology, Inc. (PYXS) stock. Of the recent 25 rating actions, 0 were upgrades and 1 were downgrades. 9 analysts currently cover PYXS.
Analyst Recommendation Trends
PYXS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.7% YoY
Revenue Next Year
$4M
↑ 8063.3% YoY
EPS This Year
$-1.25
EPS Next Year
$-1.25
↑ 0.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast PYXS EPS of $-1.25 for the current fiscal year, based on estimates from 6 analysts. The PYXS revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PYXS stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PYXS price target is $5.50 (+225.4% upside), with an analyst consensus of Buy.
The PYXS short-term stock prediction for tomorrow is $1.61 (-5.00%).
Pyxis Oncology, Inc. trades on NASDAQ under the ticker PYXS. The PYXS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 78% of covering analysts.
Frequently asked questions
PYXS forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month PYXS price target is $5.50, with a high forecast of $6.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +225.4% potential upside from the current price of $1.69.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.